Ken Griffin An2 Therapeutics, Inc. Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.93 - $3.76 $5,259 - $10,246	-2,725 Reduced 0.18%	1,553,829 $3.34 Million
Q1 2024 May 15, 2024	SELL	$2.78 - $21.53 $800 - $6,200	-288 Reduced 0.02%	1,556,554 $5.06 Million
Q4 2023 Feb 14, 2024	BUY	$13.92 - $21.0 $4,036 - $6,090	290 Added 0.02%	1,556,842 $31.9 Million
Q3 2023 Nov 14, 2023	BUY	$7.58 - $16.08 $1.66 Million - $3.53 Million	219,569 Added 16.42%	1,556,552 $25 Million
Q2 2023 Aug 14, 2023	SELL	$5.06 - $9.91 $890 - $1,744	-176 Reduced 0.01%	1,336,983 $11.4 Million
Q1 2023 May 15, 2023	BUY	$7.94 - $15.6 $1,397 - $2,745	176 Added 0.01%	1,337,159 $13.2 Million
Q3 2022 Nov 14, 2022	BUY	$7.61 - $22.29 $24,100 - $70,592	3,167 Added 0.24%	1,336,983 $23.2 Million

13.5M

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $20.8M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.